Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcomaenglish
ID: GL 11-11 Jul 2012
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Women with inoperable, locally advanced, recurrent, or metastatic uterine LMS.
Intended Guideline Users
Medical oncologists, gynecologic oncologists, general surgeons, radiation oncologists, pharmacists, and other clinicans who take care of the above target patients.
- Does chemotherapy (i.e., gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin) improve clinical outcomes (i.e., tumour response rate, progression-free survival [PFS], overall survival [OS], toxicity, or quality of life [QOL]) in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma (LMS)?
- Is there a difference in tumour response rate to chemotherapy (i.e., gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin) between recurrent pelvic disease compared with extra-pelvic metastases in patients with uterine LMS?
Full Report (PDF) (578.72 KB)